Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition.

Saved in:
Bibliographic Details
Title: Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition.
Authors: DuBose E; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Department of Cell Biology and Physiology, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Bevill SM; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Department of Cell Biology and Physiology, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Mitchell DK; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States., Sciaky N; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Golitz BT; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Dixon SAH; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States., Rhodes SD; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States.; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, United States.; Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Indiana University School of Medicine, Indianapolis, IN, United States., Bear JE; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Department of Cell Biology and Physiology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Johnson GL; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Angus SP; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States.; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.; Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Indiana University School of Medicine, Indianapolis, IN, United States.; Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN, United States.
Source: Frontiers in oncology [Front Oncol] 2024 May 16; Vol. 14, pp. 1191217. Date of Electronic Publication: 2024 May 16 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2234-943X
DOI:10.3389/fonc.2024.1191217